Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms (PROMISE)
Prospective, Multi-center, Open-label, Non-inferiority, Randomized, Cotrolled Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Huina Lu
- Phone Number: 15901703529
- Email: HuiNa.Lu@microport.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China
- Recruiting
- First Affiliated Hospital of Zhengzhou University
-
Contact:
- Sheng Guan
- Email: gsradio@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At the time of signing the informed consent form(ICF), the applicant shall be male or non-pregnant female, aged 18 to 80 years;
- Target aneurysms was diagnosed as intracranial wide-necked saccular aneurysms(neck ≥4mm, or body-neck ratio <2) by DSA/CTA/MRA;
- The diameter of the parent vessel should be 2.0 to 4.5mm;
- The target aneurysm should be suitable for stent-assisted coiling surgery and could be treated through one operation;
- Subject or its legal representative should be able to understand the purpose of this study, also agree to comply with protocol and sign the informed consent form voluntarily.
Exclusion Criteria:
- Subject whose mRS score was greater or equal to 3 during the clinical evaluation before enrollment;
- Subject with recurrent aneurysm which was already embolized through stent-assisted coiling surgery;
- Subject with multiple aneurysms that cannot be treated by single stent;
- Subject with aneurysm ruptured within 30 days;
- Subject who is not suitable for anesthesia or endovascular surgery;
- Subject with significant stenosis of the parent arterty(>50%)
- Subject who underwent major sugical procedure (such as internal fixation for limb fractures, tumor resection, surgery for vital organs, etc.) within 30 days before signing the ICF or would underwent major sugical procedure 60 days after signing the ICF;
- Subject who is currently participating in a clinical trial of another drug or device which has not met the primary endpoint, or who are expexted to participate in a clinical trial of another durg or device;
- Subject with conditions or pathological changes which may interfere with the use of instrument, including but not limited to: carotid artery dissection, vasculitis, aortic dissection, etc;
- Subject who is contraindicated with stent-assisted coiling:
Subject with allergy to required anti-platelet and/or heparin medications required for treatment; Subject with allergy to radiographic contrast; Subject with allergy to Nitinol, platinum-tungsten, platinum-iridium alloy.
- Women who is pregnant or now breastfeeding;
- Subject with a life expectancy less than 12 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: experimental group
Microport NeuroTech Intracranial Visualized Stent
|
Intracranial stent for wide-necked aneurysms
|
|
Active Comparator: control group
LVIS™ and LVIS™ Jr
|
Intracranial stent for wide-necked aneurysms
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adequate occlusion rate of aneurysms
Time Frame: Time Frame: 360±60 days
|
The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion postoperatively or at the time of primary endpoint assessment (12 months).
Occlusion rates were reported as Class I: complete occlusion; Class II: residual neck; Class III: residual aneurysm.
Adequate occlusion rate includes Class I and Class II.
|
Time Frame: 360±60 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete occlusion rate of aneurysms
Time Frame: Time Frame: 360±30 days
|
The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion postoperatively or at the time of primary endpoint assessment (12 months).
Occlusion rates were reported as Class I: complete occlusion; Class II: residual neck; Class III: residual aneurysm.
Complete occlusion rate includes Class I
|
Time Frame: 360±30 days
|
|
Retreatment rate
Time Frame: Time Frame: 360±30 days
|
Percentage of subjects who had aneurysm recurrence and underwent a secondary suergry during follow-up
|
Time Frame: 360±30 days
|
|
Successful stent placement
Time Frame: Intraoperation
|
Successful stent placement was defined as the stent was successfully released at the appropriate position, and covered the aneurysm's neck completely while the parent artery remained unobstructed postoperatively.
|
Intraoperation
|
|
Incidence od in-stent stenosis (≥50%)
Time Frame: Time Frame: 360±30 days
|
Time Frame: 360±30 days
|
|
|
Incidence of device-relared stroke or death
Time Frame: perioperative
|
perioperative
|
|
|
Incidence of ipsilateral stroke of neurological death
Time Frame: Time Frame: 360±30 days
|
Time Frame: 360±30 days
|
|
|
Incidence of device-related severe adverse event
Time Frame: Time Frame: 360±30 days
|
Time Frame: 360±30 days
|
|
|
Incidence of aneurysm rupture
Time Frame: Time Frame: 360±30 days
|
Time Frame: 360±30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Mermaid-2021-01-A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.